Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tirzepatide for Obesity Treatment and Diabetes Prevention.
Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I; SURMOUNT-1 Investigators. Jastreboff AM, et al. Among authors: perreault l. N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819. Online ahead of print. N Engl J Med. 2024. PMID: 39536238
Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes.
Harman NL, Wilding JPH, Curry D, Harris J, Logue J, Pemberton RJ, Perreault L, Thompson G, Tunis S, Williamson PR; SCORE-IT Study Team. Harman NL, et al. Among authors: perreault l. BMJ Open Diabetes Res Care. 2019 Dec 29;7(1):e000700. doi: 10.1136/bmjdrc-2019-000700. eCollection 2019. BMJ Open Diabetes Res Care. 2019. PMID: 31908789 Free PMC article.
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Davies M, et al. Among authors: perreault l. Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2. Lancet. 2021. PMID: 33667417 Clinical Trial.
Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program.
Chen ZZ, Liu J, Morningstar J, Heckman-Stoddard BM, Lee CG, Dagogo-Jack S, Ferguson JF, Hamman RF, Knowler WC, Mather KJ, Perreault L, Florez JC, Wang TJ, Clish C, Temprosa M, Gerszten RE; Diabetes Prevention Program Research Group. Chen ZZ, et al. Among authors: perreault l. Diabetes. 2019 Dec;68(12):2337-2349. doi: 10.2337/db19-0236. Epub 2019 Oct 3. Diabetes. 2019. PMID: 31582408 Free PMC article. Clinical Trial.
Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
Apolzan JW, Venditti EM, Edelstein SL, Knowler WC, Dabelea D, Boyko EJ, Pi-Sunyer X, Kalyani RR, Franks PW, Srikanthan P, Gadde KM; Diabetes Prevention Program Research Group. Apolzan JW, et al. Ann Intern Med. 2019 May 21;170(10):682-690. doi: 10.7326/M18-1605. Epub 2019 Apr 23. Ann Intern Med. 2019. PMID: 31009939 Free PMC article. Clinical Trial.
Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.
Lee CG, Heckman-Stoddard B, Dabelea D, Gadde KM, Ehrmann D, Ford L, Prorok P, Boyko EJ, Pi-Sunyer X, Wallia A, Knowler WC, Crandall JP, Temprosa M; Diabetes Prevention Program Research Group; Diabetes Prevention Program Research Group:. Lee CG, et al. Diabetes Care. 2021 Dec;44(12):2775-2782. doi: 10.2337/dc21-1046. Epub 2021 Oct 25. Diabetes Care. 2021. PMID: 34697033 Free PMC article. Clinical Trial.
171 results